3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
1484
Neoplasms
1101
Carcinoma, Non-Small-Cell Lung
918
Prostatic Neoplasms
802
Multiple Myeloma
586
Colorectal Neoplasms
535
Leukemia, Myeloid, Acute
505
Lung Neoplasms
489
Lymphoma
455
Melanoma
454
Neoplasm Metastasis
451
Lymphoma, Non-Hodgkin
416
Leukemia
409
Leukemia, Lymphocytic, Chronic, B-Cell
366
Ovarian Neoplasms
357
Pancreatic Neoplasms
338
Precursor Cell Lymphoblastic Leukemia-Lymphoma
334
Recurrence
315
Head and Neck Neoplasms
298
Lymphoma, Follicular
297
Myelodysplastic Syndromes
282
Carcinoma, Renal Cell
272
Glioblastoma
266
Brain Neoplasms
265
Hodgkin Disease
260
Lymphoma, Large B-Cell, Diffuse
255
Carcinoma, Hepatocellular
241
Lymphoma, Mantle-Cell
219
Squamous Cell Carcinoma of Head and Neck
214
Stomach Neoplasms
210
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Has results
×
Advanced Unresectable or Metastatic Solid Malignancy
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts